These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 27153151)
1. A Small Dibromotyrosine Derivative Purified From Pseudoceratina Sp. Suppresses TGF-β Responsiveness by Inhibiting TGF-β Type I Receptor Serine/Threonine Kinase Activity. Chen CL; Kao YC; Yang PH; Sung PJ; Wen ZH; Chen JJ; Huang YB; Chen PY J Cell Biochem; 2016 Dec; 117(12):2800-2814. PubMed ID: 27153151 [TBL] [Abstract][Full Text] [Related]
2. EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cells. Park CY; Kim DK; Sheen YY Cancer Sci; 2011 Oct; 102(10):1889-96. PubMed ID: 21707864 [TBL] [Abstract][Full Text] [Related]
3. EW-7195, a novel inhibitor of ALK5 kinase inhibits EMT and breast cancer metastasis to lung. Park CY; Son JY; Jin CH; Nam JS; Kim DK; Sheen YY Eur J Cancer; 2011 Nov; 47(17):2642-53. PubMed ID: 21852112 [TBL] [Abstract][Full Text] [Related]
4. BIX02189 inhibits TGF-β1-induced lung cancer cell metastasis by directly targeting TGF-β type I receptor. Park SJ; Choi YS; Lee S; Lee YJ; Hong S; Han S; Kim BC Cancer Lett; 2016 Oct; 381(2):314-22. PubMed ID: 27543359 [TBL] [Abstract][Full Text] [Related]
5. SB-505124 is a selective inhibitor of transforming growth factor-beta type I receptors ALK4, ALK5, and ALK7. DaCosta Byfield S; Major C; Laping NJ; Roberts AB Mol Pharmacol; 2004 Mar; 65(3):744-52. PubMed ID: 14978253 [TBL] [Abstract][Full Text] [Related]
6. Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. Schniewind B; Groth S; Sebens Müerköster S; Sipos B; Schäfer H; Kalthoff H; Fändrich F; Ungefroren H Oncogene; 2007 Jul; 26(33):4850-62. PubMed ID: 17297450 [TBL] [Abstract][Full Text] [Related]
7. Augmenter of liver regeneration inhibits TGF-β1-induced renal tubular epithelial-to-mesenchymal transition via suppressing TβR II expression in vitro. Liao XH; Zhang L; Chen GT; Yan RY; Sun H; Guo H; Liu Q Exp Cell Res; 2014 Oct; 327(2):287-96. PubMed ID: 25092350 [TBL] [Abstract][Full Text] [Related]
8. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. Inman GJ; Nicolás FJ; Callahan JF; Harling JD; Gaster LM; Reith AD; Laping NJ; Hill CS Mol Pharmacol; 2002 Jul; 62(1):65-74. PubMed ID: 12065756 [TBL] [Abstract][Full Text] [Related]
9. Combined treatment with erlotinib and a transforming growth factor-β type I receptor inhibitor effectively suppresses the enhanced motility of erlotinib-resistant non-small-cell lung cancer cells. Serizawa M; Takahashi T; Yamamoto N; Koh Y J Thorac Oncol; 2013 Mar; 8(3):259-69. PubMed ID: 23334091 [TBL] [Abstract][Full Text] [Related]
10. Chinese medicine Bu-Fei decoction attenuates epithelial-mesenchymal transition of non-small cell lung cancer via inhibition of transforming growth factor β1 signaling pathway in vitro and in vivo. He XR; Han SY; Li XH; Zheng WX; Pang LN; Jiang ST; Li PP J Ethnopharmacol; 2017 May; 204():45-57. PubMed ID: 28412214 [TBL] [Abstract][Full Text] [Related]
12. The ALK-5 inhibitor A-83-01 inhibits Smad signaling and epithelial-to-mesenchymal transition by transforming growth factor-beta. Tojo M; Hamashima Y; Hanyu A; Kajimoto T; Saitoh M; Miyazono K; Node M; Imamura T Cancer Sci; 2005 Nov; 96(11):791-800. PubMed ID: 16271073 [TBL] [Abstract][Full Text] [Related]
13. Towards the small and the beautiful: a small dibromotyrosine derivative from Pseudoceratina sp. sponge exhibits potent apoptotic effect through targeting IKK/NFκB signaling pathway. Su JH; Chen YC; El-Shazly M; Du YC; Su CW; Tsao CW; Liu LL; Chou Y; Chang WB; Su YD; Chiang MY; Yeh YT; Lu MC Mar Drugs; 2013 Aug; 11(9):3168-85. PubMed ID: 24065159 [TBL] [Abstract][Full Text] [Related]
14. Effects of TGF-β signaling blockade on human A549 lung adenocarcinoma cell lines. Xu CC; Wu LM; Sun W; Zhang N; Chen WS; Fu XN Mol Med Rep; 2011; 4(5):1007-15. PubMed ID: 21725601 [TBL] [Abstract][Full Text] [Related]
15. Altered β1,6-GlcNAc branched N-glycans impair TGF-β-mediated epithelial-to-mesenchymal transition through Smad signalling pathway in human lung cancer. Li N; Xu H; Fan K; Liu X; Qi J; Zhao C; Yin P; Wang L; Li Z; Zha X J Cell Mol Med; 2014 Oct; 18(10):1975-91. PubMed ID: 24913443 [TBL] [Abstract][Full Text] [Related]
16. An novel inhibitor of TGF-β type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition. Park CY; Min KN; Son JY; Park SY; Nam JS; Kim DK; Sheen YY Cancer Lett; 2014 Aug; 351(1):72-80. PubMed ID: 24887560 [TBL] [Abstract][Full Text] [Related]
17. Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Subramanian G; Schwarz RE; Higgins L; McEnroe G; Chakravarty S; Dugar S; Reiss M Cancer Res; 2004 Aug; 64(15):5200-11. PubMed ID: 15289325 [TBL] [Abstract][Full Text] [Related]
18. Inhibitory effect of a TGFbeta receptor type-I inhibitor, Ki26894, on invasiveness of scirrhous gastric cancer cells. Shinto O; Yashiro M; Kawajiri H; Shimizu K; Shimizu T; Miwa A; Hirakawa K Br J Cancer; 2010 Mar; 102(5):844-51. PubMed ID: 20145621 [TBL] [Abstract][Full Text] [Related]